There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has
shown promising preclinical and clinical activity against metastatic colorectal cancer,
particularly in combination with chemotherapy.